Ticker

No recent analyst price targets found for KIO.

Latest News for KIO

KIO: High Beta Fixed Income CEF With Significant Downside (Rating Downgrade)

KKR Income Opportunities (KIO) is rated 'Sell' due to high beta, credit risk, and limited upside in the current macro environment. KIO's portfolio is now 50% single-B, 20% CCC, with a 50/50 split between leveraged loans and high yield bonds, and 10% in CLOs. With credit spreads near historic lows and economic uncertainty from oil price spikes, KIO faces significant drawdown risk if spreads widen.

Seeking Alpha • Apr 17, 2026
Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway

Encinitas, California--(Newsfile Corp. - April 14, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) today announced the publication of the results from its Phase 1 ABACUS-1 study of KIO-301 in Nature Medicine. The publication adds clinical detail to a program aimed at restoring light responsiveness with a small molecule "photoswitch" in patients with the advanced inherited retinal disease, retinitis pigmentosa.

Newsfile Corp • Apr 14, 2026
7 High-Yield Fixed Income CEFs Trading At Wide Discounts

Seven high-yield fixed income CEFs—ARDC, BGH, BIT, GHY, KIO, OPP, WDI—currently trade at wider-than-average discounts, offering yields from 10% to 14%. Market fears over private credit and macroeconomic uncertainty have pressured prices, creating potential buying opportunities for long-term income investors. These funds diversify across senior loans, high-yield bonds, CLOs, and MBS, balancing floating and fixed-rate…

Seeking Alpha • Apr 13, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

No Senate trades found for KIO.

No House trades found for KIO.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top